Onychodystrophy and its management by Oppel, Tilmann & Korting, Hans Christian
Onychodystrophy and its management
Management der Onychodystrophie
Abstract
Onychodystrophy represents various pathologic processes of the nails
suchasinfectiousandnoninfectiousdisordersincludingonychomycosis,
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psoriasis and allergic and irritant dermatitis. Nail changes may also be
a clue to other dermatological or systemic diseases. But often it is diffi-
culttoestablishthediagnosisasmostnailchangesareunspecific.The 1 Department of Dermatology
and Allergology, Ludwig- purpose of this article is to give an overview of the anatomy of the nail
Maximilians-University,
Munich, Germany
organ and possible causes of onychodystrophy. Therapeutic modalities
are reviewed as well as modes of analysis.
Zusammenfassung
OnychodystrophienrepräsentierenverschiedenepathologischeProzesse
desNagelswiebeispielsweiseinfektiöseundnichtinfektiöseErkrankun-
gen einschließlich der Onychomykose, Psoriasis und der allergischen
undirritativenKontaktdermatitis.Nagelveränderungenkönnendarüber
hinausHinweisefüranderedermatologischeoderinnereErkrankungen
geben. Häufig ist es jedoch schwierig, die Diagnose zu stellen, da die
meisten Nagelveränderungen unspezifisch sind. Gegenstand dieses
Artikels ist es, einen Überblick über die Anatomie des Nagelorgans und
möglicheUrsachenderOnychodystrophiezugeben.Therapiemodalitäten
werden ebenso kritisch gewürdigt wie Untersuchungsmethoden.
Text
Anatomy and physiology of the nail
organ
The human nail (unguis, onyx = nail), the horny covering
of the upper surface of the tip of each finger and toe, is
a set of complex structures that can most accurately be
called the nail unit. The nail unit is an entire organ con-
sisting of the nail matrix, the nail plate, the nail bed and
the nail folds (Figure 1), [1], [2], [3]. The nail plate, the
finalproductofthenailunit,isahard,relativelyinflexible
multilayeredsheetofcornifiedcells,usuallybetween0.5-
0.7 mm in thickness. Histologically, the nail plate is
formed by flattened onychocytes, derived from the cells
of the keratogenous zone of the matrix. The onychocytes
are,for the mostpart, anucleated andaresmalleron the
surface than on the buttom of the plate. The product of
these cells is onychokeratin. The nail plate is resting on
the nail bed being firmly attached. The nail bed consists
of barely proliferating, stratified cells that exhibit no mi-
toses and keratinize very gradually throughout most of
the extension of the bed. Approximately one fourth of the
nail is covered by the proximal nail fold while a small
margin of the sides of the nail plate is often occluded by
the lateral nail folds. Some authors term the lateral nail
fold and adjacent finger tissue lateral to the nail fold the
nail wall [1], [4].
The nature of onychodystrophy
Abnormalnailscanbecausedbyahugevarietyofunder-
lying diseases (Figure 2) such as fungal and nonfungal
infections, various noninfectious inflammatory dermato-
logic diseases of the nail unit and tumors. Changes in
nails can also be a sign of systemic diseases, they can
occur secondarily to systemic drug use and many other
rare or ill defined factors [5], [6]. Abnormal nails in a
stricter sense as a rule represent changes of the nail
plate characterized by dystrophy and/or dyschromia.
Onychodystrophyisawidelyused,yetrarelydefinedterm.
It refers to nail changes apart from changes of the color
called nail dyschromia. From the patient's point of view
partial or complete disruption of the various keratinous
layers of the nail plate is most relevant. In every day life
these changes are usually referred to as brittleness. For
a better understanding of nail dystrophies the origin of
the disorder should be first considered. The nail plate
can be directly altered by exogenous factors. In this case
thenailisprimarilyinvolved.Butendogenousfactorscan
also lead to a dystrophy of the nail plate. Then, changes
in matrix, proximal nail fold, nail bed, hyponychium or
underlying bony phalanx secondarily cause abnormal
nails [7]. Unfortunately, there is only little known about
the exact underlying pathophysiology leading to dys-
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a) Longitudinal section of a digit showing the nail unit (modified from [50]).
b) Corresponding image taken in a female young adult.
1) proximal nail fold, 2) lateral nail fold, 3) plate, 4) lunula, 5) cuticle, 6) matrix, 7)bed, 8) onychodermal band, 9) distal edge of
plate, 10) hyponychium
Figure 2
trophies of the nails. Nevertheless, onychodystrophy is
frequent.
Onychomycosisandnailpsoriasiscause
onychodystrophy most often
The most frequent nail disorders are onychomycosis and
nail psoriasis, both well established diseases of the nail.
Onychomycosis represents 30-40% of the nail disorders
[8]. The prevalence of nail psoriasis in patients with
psoriasis of the skin amounted to about 80% of 1.728
psoriaticpatientsexaminedbydeJongetal.[9].Clinically,
onychomycosis and nail psoriasis have to be differenti-
ated from many other types of diseases linked to ony-
chodystrophy.Toestablishtheunderlyingdiseaseleading
to nail dystrophy as a first step one should differentiate
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ingnailmaterialformicroscopicexaminationandculture.
Ifafunguscannotbeidentifiedafterrepeatingthisexam-
ination several times a nonfungal disorder should be as-
sumed. Moreover, the difficult path to the diagnosis re-
quiresacarefulexaminationnotonlyofthenailsbutalso
of the glabrous skin and mucous membranes of the pa-
tient.Sometimesnailbiopsiesarenecessary.Occupation
andcosmetichabitsofthepatientshouldbeconsidered.
Systemic drug use can induce
onychodystrophy
Beside onychomycosis and nail psoriasis systemic drugs
often affect the nails. Pertinent changes range from mild
pigmentation abnormalities to nail shedding and matrix
scarring. Antimicrobial and antineoplastic chemothera-
peutic agents including antimalarials as well as other
drugs and poisons affect the nail in numerous ways [10].
E.g., dyschromia and dystrophy of the nail plate occured
after treatment with the antineoplastic drug docetaxel
[11] and after treatment of rheumatoid arthritis with
penicillamine [12]. Paronychia was described in associ-
ation with the HIV protease inhibitor indinavir [13]. It is
difficult to categorize the mechanism by which the nail
change occurs. Most often toxicity to the matrix, to the
nail bed or hyponychial region and to the periungual
structures is assumed. Although the exact cause of the
nailchangesisunclear,ischemia,edemaanddisturbance
of the cellular maturation is likely to play a major role
[10].Themostcommonmechanismofactionofantibiot-
icslikethetetracyclinefamilyisrelativelywellunderstood:
photosensitivity leads to onycholysis. But antibiotics also
induce Beau's lines, nonspecific nail dystrophy and nail
shedding [10]. Overall, as nail changes are most often
not unique it mayby difficult to incriminate a single drug.
Eczema of the fingertips and nail unit
results in onychodystrophy
Just as endogenous factors like systemic drugs also
exogenous factors can lead to a dystrophy of the nail
plate. But in this case it is often laborious to find out the
relevant external agents. Guin et al. [14] reported about
three patients with prominent fingernail dystrophy and
fingertip eczema. All patients were patch-test positive to
cyanoacrylate used as an adhesive on artificial plastic
fingernails. In addition, methyl methacrylate monomers
and formaldehyde are known sensitizers and lead via al-
lergic contact dermatitis to onycholysis through involve-
mentof the subungualand periungualtissues[15], [16].
Marrenetal.[17]reportedaboutanoccupationalcontact
dermatitis which presented as nail dystrophy due to
quaternium 15, which is commonly found in cosmetics
and skin care products. In this case nail dystrophy pre-
cededthehandeczemabyseveralweeks.Consequently,
patch testing should be performed to detect contact
sensitivities to identify an underlying allergic contact
dermatitis in patients presenting with nail dystrophy.
Moreover, it is worth noting that contact sensitivities in-
volving the nails cause a distal dystrophy corresponding
with the area of contact with the allergen. Thus, as a
useful clinical sign, the nail matrix and proximal portions
ofthegrowingnailareunaffected.Justasallergiccontact
dermatitis also irritant dermatitis can cause onychodys-
trophy. Prolonged immersion in water plus repetitive
mechanical trauma might be most often responsible for
irritantdermatitisofthenails.Furthermore,naildystrophy
due to irritant dermatitis was observed after repetitive
contactwithsugar,enzymedetergents,sodiumhypochlor-
ite and hydrofluoric acid [16]. We think that isolated or
repetitivemechanicaltrauma,dehydrationofthenailand
prolonged exposure to liquids, alkali and solvents are an
underestimated cause of nail dystrophy. We propose the
existence of a dermatits primarily affecting the nail and
suggest the term onychitis which should be further clas-
sified as irritant or allergic (Figure 3, (Figure 4. To clarify
the exact reason it is obvious that the patient should be
carefullyquestionedabouthisorheroccupation,cosmetic
habits and previous therapy.
Aspects of the influence of
onychodystrophy on quality of life
Diseases of the nail are underscored but it is likely that
onychodystrophy affects quality of life including physical
and social functioning and emotional health. Common
complaints of patients with onychomycosis are nail trim-
ming problems, difficulty to walk, discomfort in wearing
shoes,pain,nailpressureandembarrassment[18],[19].
Extensive fingernail involvement and disability is noted
because of the need for fingernails in picking up small
objects like buttons and coins [19]. In order to measure
the impact of onychomycosis on patient quality of life
Turner and Testa [20] developed an onychomycosis dis-
ease-specific questionnaire that assessed symptom dis-
tress, functional impact and social stigma associated
with the disease. Significant differences in physical
functioning,emotionalhealthandsocialfunctioningwere
foundbetweenclinicallycured,improvedorfailedpatients
[20]. In light of its complications such as cellulitis, pain
and extensive dermatophytic infections onychomycosis
should be considered a medical condition that deserves
rigorous clinical management [18]. Psoriasis of the nails
also influences quality of life. About 52% of the patients
who were interviewed by de Jong et al. [9] suffered from
pain caused by their nail changes and a large subgroup
of these patients was restricted in their daily activities,
housekeeping and profession.
Measurement of nail growth and the
corresponding influence of drugs
Clinicians used to observing the slow rate of clearence
of diseased or damaged nails tend to see the nail appar-
atus as a static and inert tissue. However, to answer the
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Figure 4: Dermatitis of the nails in a patient with atopy
question whether nails are alive or dead one should
realize that the germinative layers of the nail matrix con-
tinuetodivide,undertakeDNAsynthesisanddifferentiate
to produce the nail plate throughout life. Thus with the
criterium of growth nails fulfil a hallmark of life [21]. Nail
growth has been studied by many authors employing
several different methods; e.g., observation of the distal
movement of a reference point on the nail plate [21],
following up changes in the volume of nail indentations
drilled with a dental burr until they grow out of the nail
[22]andexaminationofthemicroreliefofthenailsurface
by computerized optical profilometry [23]. Nail growth
can lead to elongation or thickening of the nail plate.
Normal fingernail growth is assumed to vary from less
than 1.8 and to more than 4.5 mm per month [24]. The
middle finger shows the greatest rate, while thumb and
little finger show the slowest rate of nail growth [25].
Several factors affect nail growth [21]. Faster growth is
observedduringdaytime,pregnancy,insummer,onright
hand nails, due to minor trauma and in patients with
psoriasis,pityriasisrubrapilarisandhyperthyroidism.Old
age, cold environment, immobility, poor nutrition, hypo-
thyroidism as well as some rare and unusual conditions
such as the yellow nail syndrome lead to slower growth
of the nails [21]. But whereas nails grow more slowly in
older people they become thicker. Thus, the same unit
massofnailmightbeformedeachdayalsoinoldpeople.
Nail growth measurements in a patient with yellow nail
syndromerevealedthatlongitudinalgrowthintheaffected
thumb nail was half that in the normal thumb nail. How-
ever, nail thickness in the yellow nail was double that in
the normal nail [26]. Moffit and de Berker [26] suggest
that the nail that grows half as fast grows twice as thick.
Thus, rate of longitudinal growth does not necessarily
reflect nail plate production. The authors speculate that
in yellow nail syndrome the rate of nail production by the
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nails, but that some factor causes an altered orientation
of nail growth in the abnormal nail [26]. It is commonly
believedthatyellownailsyndromewhichischaracterized
by the classical triad of lymphedema, recurrent pleural
effusion and yellow nails is due to an abnormality of the
lymphatic vessels. D'Alessandro et al. [27] speculated
thatincreasedmicrovascularpermeabilityduetocapillary
leakage and associated hypoalbuminaemia may contrib-
ute to the pathogenesis of this syndrome. Finally, they
foundaseveremicroangiopathybynailfoldcapillaroscopy
and photoplethysmography of both hands. Thus, in addi-
tion to lymphatic abnormality microangiopathy and in-
creased microvascular filtration at pleura, intestine and
limbs could play a role in this syndrome [27].
Increased longitudinal nail growth was reported for vari-
ous drugs. De Doncker and Pierard [23] demonstrated a
dose-dependent increase of the growth rate of infected
nailsforthetriazoleantifungalitraconazole.But,asfungal
infections of the nail unit slow down nail growth, it is un-
clear whether itraconazole primarily accelerates the
turnover rate of matrix cells [23].
Anincreaseinlongitudinalnailgrowthwasalsoobserved
in psoriatics who were treated with retinoids, whereas
treatmentwithetretinatehadnoeffectonthedailygrowth
rate of patients with other dermatoses which are known
to have a good response to aromatic retinoids [28].
Treatment with topical Vitamin E led to clinical improve-
ment of nail changes in yellow nail syndrome with a cor-
responding increase in nail growth rates [29]. Improve-
ment of yellow nails was also found following treatment
with oral vitamin E and more discernible subsequent to
theintroductionofitraconazolepulsetherapyforsecond-
aryonychomycosissuggestinganeffectofthistreatment
on ungual growth [30]. However, patients expect from
theirnailnormalcolorandstructureratherthanincreased
growth [31]. Thus, patients would be rather interested in
a nail plate normalizer than a nail growth enhancer as
such. In particular for the huge variety of non-onychomy-
cosis nail diseases there is a big demand for additional
options of drug treatment.
Further approaches to objective
measurement of treatment effects
Eveniftherapeuticeffectscanbeevaluatedbythepatient
and the physician it would be desirable to have further
objectivemeasuringsystems.Potentialobjectiveparamet-
ers of healthy nails are thickness and volume of the nail
and volume of the matrix as well. 20 MHz ultrasound of-
fers an objective, but noninvasive, method to investigate
these parameters showing characteristic quantitative
changes in different skin diseases [32]. Using this tech-
nique Wollina et al. demonstrated that in patients with
systemic lupus erythematosus nail thickness and matrix
volumewereincreased,whereaspatientswithprogressive
systemic sclerosis showed a decrease in nail thickness
and matrix volume. Unfortunately, in other diseases in-
cluding psoriasis, eczema, onychomycosis and brittle
nails these measurements disclosed no confident differ-
ences to healthy controls [32]. Scanning electron micro-
scopy is another interesting method for analyzing the
structureofnails.Processingnailedgeclippingsthusthe
thicknessofthenailscanbemeasured,lamellarsplitting
and dorsal nail surface can be assessed in order to cor-
roborate clinical results of therapeutic strategies [33].
Also, high-resolution magnetic resonance imaging (MRI)
provides a new tool for the investigation of pathology of
the nail apparatus and might be also useful in the dia-
gnosis and clarification of the physiopathology of under-
lying diseases of onychodystrophy. While the diagnostic
value of these methods seems obvious they seemingly
have not yet been evaluated in drug trials.
Therapeutic aspects: systemic therapy
of onychodystrophy
Various topical and systemic therapies have been per-
formed to investigate their potential beneficial role in
disordersofthenail.Themodernandeffectiveantifungal
agents itraconazole, fluconazole and terbinafine are of
special interest as onychomycoses represent the most
frequently seen nail diseases. Evans and Sigurgeirsson
[34] demonstrated a clinical cure rate of 60%, a mycolo-
gical cure rate of about 80% and a complete cure rate
(clinical and mycologic cure) of 55% at week 72 in pa-
tientswithtoenailonychomycosistreatedwithterbinafine
250mg/d for 16 weeks. Also a long term benefit was
observed by Bräutigam et al. [35] who followed up pa-
tients three years after a successful treatment of toenail
mycosis with terbinafine and itraconazole. Thus, at least
in part onychodystrophy is curable if antagonizing the
pathogeneticallyrelevantreason.However,about20-30%
of the patients must expect treatment failure or relapse
following treatment of onychomycosis [36]. A possible
advance towards higher cure rates might be the combin-
ation of drugs to produce synergistic activity [36], [37].
Predisposing factors for onychomycosis [38], [39], [40]
arearterialandvenouscirculationdisorders,neuropathy,
diabetesmellitus,traumaandanosteoarticularpathology
like defective position of the feet. However, these dis-
easescanindependentlyleadtoonychodystrophy,which
oftencannotbedistinguishedfromsubungualonychomy-
cosis and perhaps existed before mycological infection
occured. This must be also considered if nails remain
dystrophic after mycologically speaking successful anti-
mycotic therapy.
Amongst the general public there is a widespread belief
that supplementation of calcium improves quality of fin-
gernails and toenails. However, a randomized, placebo-
controlled trial provided no support for the idea that diet-
ary calcium intake alters nail quality in healthy postmen-
opausal women [41].
A favourable response to oral application of biotin for
defect hooves of horses or claws of pigs has been docu-
mentedinveterinarymedicine.Forsomehumanpatients
with brittle fingernails and onychoschizia an effective
therapy with biotin was described resulting in increased
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duced splitting, yet not in double blind controlled trials
[33], [42], [43]. Generalized hyperpigmentation of skin
and nails in a patient with vitamin B12 deficiency due to
pernicious anemia returned to normal after treatment
with intramuscular cyanocobalamin [44].
Therapeutic aspects: topical therapy of
onychodystrophy
Topical and intralesional glucocorticoid applied to the
proximalnailfoldfortherapyofnaildystrophyassociated
with various underlying skin disorders such as atopic
dermatitis, psoriasis and lichen planus are regarded as
safe and acceptable treatment options [45], [46], [47].
In the treatmentof nail psoriasis topical calcipotriol shall
represent an effective and safe alternative [46]. While
topical and in particular intralesional treatment is com-
mon, for the patient this therapy is time-consuming and
disappointing if there is no marked improvement. It is
assumedthattopicalglucocorticoidtherapyunderplastic
film occlusion increases efficacy. It has been shown that
in dystrophic psoriatic fingernails the nail penetration
enhancerBelanyx®(urea,propyleneglycol)improvesthe
nail pitting area, number of nail pits, subungal keratosis,
onycholysis and oil spots [48]. It could be also demon-
strated that additionof 1% fluorouracilto Belanyx® does
not increase the efficacy of the active agent in psoriatic
nail dystrophy [48].
Conclusions
In conclusion, onychodystrophy by principle is open to
effectivetreatment.Thisinparticularappliestoonychodys-
trophy caused by onychomycosis. As noninfectious ony-
chodystrophyseemstobelinkedmostoftentoexogenous
damaging factors it looks rewarding to search for them
vigorously to make consequent avoidance feasible. Nev-
ertheless,thereclearlystillismedicalneedforadditional
options of drug treatment. Current approaches too often
still disappoint patients. Moreover, the wanted effects
attributed to them as a rule are not well backed by ad-
equate clinical trials.
The nail plate is a difficult barrier for drugs to penetrate.
Therefore, the bioavailability of drugs after topical or oral
administration in the nail plate represents a pivotal
problem of nail therapy. To be effective the drug must
successfully penetrate the keratinized tissue. For the
nails,especiallythetoenails,penetrationafteroraladmin-
istration is impeded by their slow growth and by specific
conditions that retard the rate of nail growth, such as
advanced age and yellow nail syndrome. Adequately de-
vised nail patches might prove to be at least one useful
solution to the problem.
We suppose that irritant dermatitis of the nails is an un-
derestimatedreasonforonychodystrophy.Barriercreams
were shown to be efficient improving the clinical skin
status and stratum corneum hydration in the treatment
of occupational irritant contact dermatitis of glabrous
skin [49]. If applicable the development of a protection
lacquer with a barrier function for the nail plate might
help preventing irritant onychitis in the future.
References
1. González-Serva A. Structure and function. In: Scher RK, Daniel
CR, editors. Nails: therapy, diagnosis, surgery. Philadelphia,
London: Saunders, 1990:11-30.
2. Scher RK. Nail surgery. Clin Dermatol 1987;5:135-142.
3. Runne U, Orfanos CE. The human nail: structure, growth and
pathological changes. Curr Probl Dermatol 1981;9:102-149.
4. Dawber RPR, de Berker DAR, Baran R. Science of the nail
apparatus. In: Baran R, Dawber RPR, de Berker DAR, Haneke E,
Tosti A, editors. Baran and Dawber's diseases of the nails and
their management. 3 ed. Oxford, London: Blackwell Science,
2001:1-47.
5. Scher RK, Daniel CR. Nails: therapy, diagnosis, surgery.
Philadelphia, London: Saunders, 1990.
6. Tosti A, Piraccini BM. Treatment of common nail disorders.
Dermatol Clin 2000;18:339-348.
7. Baran R, Kechijian P. Understanding nail disorders. Eur J
Dermatol 2001;11:159-162.
8. Haneke E. Fungal infections of the nail. Semin Dermatol
1991;10:41-53.
9. de Jong EM, Seegers BA, Gulinck MK, Boezeman JB, van de
Kerkhof PC. Psoriasis of the nails associated with disability in a
largenumberofpatients:resultsofarecentinterviewwith1,728
patients. Dermatology 1996;193:300-303.
10. Daniel CR, Scher RK. Nail changes secondary to systemic drugs
or ingestants. J Am Acad Dermatol 1984;10:250-258.
11. Correia O, Azevedo C, Pinto Ferreira E, Braga Cruz F, Polonia J.
Nail changes secondary to docetaxel (Taxotere). Dermatology
1999;198:288-290.
12. Bjellerup M. Nail-changes induced by penicillamine. Acta Derm
Venereol 1989;69:339-341.
13. Colson AE, Sax PE, Keller MJ, Turk BK, Pettus PT, Platt R, et al.
Paronychia in association with indinavir treatment. Clin Infect
Dis 2001;32:140-143.
14. Guin JD, Baas K, Nelson-Adesokan P. Contact sensitization to
cyanoacrylate adhesive as a cause of severe onychodystrophy.
Int J Dermatol 1998;37:31-36.
15. Kassis V, Vedel P, Darre E. Contact dermatitis to methyl
methacrylate. Contact Dermatitis 1984;11:26-28.
16. KernDG.OccupationalDisease.In:ScherRK,DanielCR,editors.
Nails: therapy, diagnosis, surgery. Philadelphia, London:
Saunders, 1990:224-243.
17. Marren P, de Berker D, Dawber RP, Powell S. Occupational
contact dermatitis due to quaternium 15 presenting as nail
dystrophy. Contact Dermatitis 1991;25:253-255.
18. Elewski BE. Onychomycosis. Treatment, quality of life, and
economic issues. Am J Clin Dermatol 2000;1:19-26.
19. Millikan LE, Powell DW, Drake LA. Quality of life for patients with
onychomycosis. Int J Dermatol 1999;38 Suppl 2:13-16.
20. Turner RR, Testa MA. Measuring the impact of onychomycosis
on patient quality of life. Qual Life Res 2000;9:39-53.
21. Dawber R, Baran R. Nail growth. Cutis 1987;39:99-103.
6/7 German Medical Science 2003, Vol. 1, ISSN 1612-3174
Oppel et al.: Onychodystrophy and its management22. Heikkila H, Stubb S, Kiistala U. Nail growth measurement
employing nail indentation--an experimental follow-up study of
nail growth in situ. Clin Exp Dermatol 1996;21:96-99.
23. Doncker PD, Pierard GE. Acquired nail beading in patients
receiving itraconazole-anindicator of faster nail growth? A study
usingopticalprofilometry.ClinExpDermatol1994;19:404-406.
24. HamiltonJB,TeradaH,MestlerGE.Studiesofgrowththroughout
the lifespan in Japanese: Growth and size of nails and their
relationshipto age, sex, hereditary, and other factors. J Gerontol
1955;10:401.
25. Le Gros CW, Buxton LDH. Studies in nail growth. Br J Dermatol
1938;50:221-235.
26. Moffitt DL, de Berker DA. Yellow nail syndrome: the nail that
grows half as fast grows twice as thick. Clin Exp Dermatol
2000;25:21-23.
27. D'AlessandroA,MuziG,MonacoA,FilibertoS,BarboniA,Abbritti
G. Yellow nail syndrome: does protein leakage play a role? Eur
Respir J 2001;17:149-152.
28. GalosiA,PlewigG,Braun-FalcoO.Theeffectofaromaticretinoid
Ro10-9359(etretinate)onfingernailgrowth.ArchDermatolRes
1985;277:138-140.
29. Williams HC, Buffham R, du Vivier A. Successful use of topical
vitamin E solution in the treatment of nail changes in yellow nail
syndrome. Arch Dermatol 1991;127:1023-1028.
30. Luyten C, Andre J, Walraevens C, De Doncker P. Yellow nail
syndrome and onychomycosis. Experience with itraconazole
pulse therapy combined with vitamin E. Dermatology
1996;192:406-408.
31. Draelos ZD. Nail cosmetic issues. Dermatol Clin 2000;18:675-
683.
32. Wollina U, Berger M, Karte K. Calculation of nail plate and nail
matrix parameters by 20 MHz ultrasound in healthy volunteers
and patientswith skin disease.Skin Res Technol2001;7:60-64.
33. Colombo VE, Gerber F, Bronhofer M, Floersheim GL. Treatment
of brittle fingernails and onychoschizia with biotin: scanning
electron microscopy. J Am Acad Dermatol 1990;23:1127-1132.
34. Evans EG, Sigurgeirsson B. Double blind, randomised study of
continuous terbinafine compared with intermittent itraconazole
in treatment of toenail onychomycosis. The LION Study Group.
Brit Med J 1999;318:1031-1035.
35. Bräutigam M, Weidinger G, Nolting S. Successful treatment of
toenailmycosiswithterbinafineanditraconazolegiveslongterm
benefits [letter]. Brit Med J 1998;317:1084.
36. Evans EG. The rationale for combination therapy. Br J Dermatol
2001;145 Suppl 60:9-13.
37. Gupta AK, Baran R. Ciclopirox nail lacquer solution 8% in the
21st century. J Am Acad Dermatol 2000;43:S96-102.
38. Haneke E, Roseeuw D. The scope of onychomycosis:
epidemiologyandclinicalfeatures.IntJDermatol1999;38Suppl
2:7-12.
39. Abeck D, Haneke E, Nolting S, Reinel D, Seebacher C.
Onychomykose. Dt Ärztebl 2000;97:A1984-1986.
40. Abeck D, Gruseck E, Korting HC, Ring J. Onychomykose:
Epidemiologie,Pathogenese,Klinik,MikrobiologieundTherapie.
Dt Ärztebl 1996;93:A2027-2032.
41. Reid IR. Calcium supplements and nail quality. N Engl J Med
2000;343:1817.
42. Hochman LG, Scher RK, Meyerson MS. Brittle nails: response to
daily biotin supplementation. Cutis 1993;51:303-305.
43. Floersheim GL. Behandlung brüchiger Fingernägel mit Biotin. Z
Hautkr 1989;64:41-48.
44. NoppakunN,SwasdikulD.Reversiblehyperpigmentationofskin
and nails with white hair due to vitamin B12 deficiency. Arch
Dermatol 1986;122:896-899.
45. Khoo BP, Giam YC. A pilot study on the role of intralesional
triamcinolone acetonide in the treatment of pitted nails in
children. Singapore Med J 2000;41:66-68.
46. Tosti A, Piraccini BM, Cameli N, Kokely F, Plozzer C, Cannata GE,
et al. Calcipotriol ointment in nail psoriasis: a controlled double-
blindcomparisonwithbetamethasonedipropionateandsalicylic
acid. Br J Dermatol 1998;139:655-659.
47. Piraccini BM, Tosti A, Iorizzo M, Misciali C. Pustular psoriasis of
the nails: treatment and long-term follow-up of 46 patients. Br J
Dermatol 2001;144:1000-1005.
48. de Jong EM, Menke HE, van Praag MC, van De Kerkhof PC.
Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in
a nail penetration-enhancing vehicle: a double-blind study.
Dermatology 1999;199:313-318.
49. Berndt U, Wigger-Alberti W, Gabard B, Elsner P. Efficacy of a
barrier cream and its vehicle as protective measures against
occupational irritant contact dermatitis. Contact Dermatitis
2000;42:77-80.
50. Haneke E. Erkrankungen der Nägel. In: Plewig G, Korting HC,
eds. Fortschritte der praktischen Dermatologie und Venerologie
1994 (14). Berlin: Springer, 1995: 204-210.
Corresponding author:
Prof. Dr. Hans Christian Korting
Klinik und Poliklinik für Dermatologie und Allergologie,
Ludwig-Maximilians-Universität München, Frauenlobstr.
9-11, 80337 München, Germany, Tel. +49-89-5160-
6203, Fax +49-89-5160-6204
H.C.Korting@lrz@uni-muenchen.de
Please cite as
Oppel T, Korting HC. Onychodystrophy and its management. Ger Med
Sci. 2003;1:Doc02.
This article is freely available from
http://www.egms.de/en/gms/2003-1/000002.shtml
Received: 2003-05-02
Published: 2003-07-01
Copyright
©2003 Oppel et al. This is an Open Access article distributed under
the terms of the Creative Commons Attribution License
(http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You
are free: to Share — to copy, distribute and transmit the work, provided
the original author and source are credited.
7/7 German Medical Science 2003, Vol. 1, ISSN 1612-3174
Oppel et al.: Onychodystrophy and its management